Justin Guinney,Tao Wang,Teemu D. Laajala,Kimberly Kanigel Winner,J. Christopher Bare,Elias Chaibub Neto,Suleiman A. Khan,Gopal Peddinti,Antti Airola,Tapio Pahikkala,Tuomas Mirtti,Thomas Yu,Brian M. Bot,Liji Shen,Kald Abdallah,Thea Norman,Stephen Friend,Gustavo Stolovitzky,Howard Soule,Christopher J. Sweeney,Charles J. Ryan,Howard I. Scher,Oliver Sartor,Yang Xie,Tero Aittokallio,Fang Liz Zhou,James C. Costello,Catalina Anghel,Helia Azima,Robert Baertsch,Pedro J. Ballester,Chris Bare,Vinayak Bhandari,Cuong C. Dang,Maria Bekker-Nielsen Dunba,Ann-Sophie Buchardt,Ljubomir Buturovic,Da Cao,Prabhakar Chalise,Junwoo Cho,Tzu-Ming Chu,R. Yates Coley,Sailesh Conjeti,Sara Correia,Ziwei Dai,Junqiang Dai,Philip Dargatz,Sam Delavarkhan,Detian Deng,Ankur Dhanik,Yu Du,Aparna Elangovan,Shellie Ellis,Laura L. Elo,Shadrielle M. Espiritu,Fan,Ashkan B. Farshi,Ana Freitas,Brooke Fridley,Christiane Fuchs,Eyal Gofer,Gopalacharyulu Peddinti,Stefan Graw,Russ Greiner,Yuanfang Guan,Jing Guo,Pankaj Gupta,Anna I. Guyer,Jiawei Han,Niels R. Hansen,Billy H. W. Chang,Outi Hirvonen,Barbara Huang,Chao Huang,Jinseub Hwang,Joseph G. Ibrahim,Vivek Jayaswal,Jouhyun Jeon,Zhicheng Ji,Deekshith Juvvadi,Sirkku Jyrkkio,Kimberly Kanigel-Winner,Amin Katouzian,Marat D. Kazanov,Shahin Khayyer,Dalho Kim,Agnieszka K. Golinska,Devin Koestler,Fernanda Kokowicz,Ivan Kondofersky,Norbert Krautenbacher,Damjan Krstajic,Luke Kumar,Christoph Kurz,Matthew Kyan,Michael Laimighofer,Eunjee Lee,Wojciech Lesinski,Miaozhu Li,Ye Li,Qiuyu Lian,Xiaotao Liang,Minseong Lim,Henry Lin,Xihui Lin,Jing Lu,Mehrad Mahmoudian,Roozbeh Manshaei,Richard Meier,Dejan Miljkovic,Krzysztof Mnich,Nassir Navab,Elias C. Neto,Yulia Newton,Subhabrata Pal,Byeongju Park,Jaykumar Patel,Swetabh Pathak,Alejandrina Pattin,Donna P. Ankerst,Jian Peng,Anne H. Petersen,Robin Philip,Stephen R. Piccolo,Sebastian Poelsterl,Aneta Polewko-Klim,Karthik Rao,Xiang Ren,Miguel Rocha,Witold R. Rudnicki,Hyunnam Ryu,Hagen Scherb,Raghav Sehgal,Fatemeh Seyednasrollah,Jingbo Shang,Bin Shao,Howard Sher,Motoki Shiga,Artem Sokolov,Julia F. Soellner,Lei Song,Josh Stuart,Ren Sun,Nazanin Tahmasebi,Kar-Tong Tan,Lisbeth Tomaziu,Joseph Usset,Yeeleng S. Vang,Roberto Vega,Vitor Vieira,David Wang,Difei Wang,Junmei Wang,Lichao Wang,Sheng Wang,Yue Wang,Russ Wolfinger,Chris Wong,Zhenke Wu,Jinfeng Xiao,Xiaohui Xie,Doris Xin,Hojin Yang,Nancy Yu,Xiang Yu,Sulmaz Zahedi,Massimiliano Zanin,Chihao Zhang,Jingwen Zhang,Shihua Zhang,Yanchun Zhang,Hongtu Zhu,Shanfeng Zhu,Yuxin Zhu

Abstract:Metastatic castration resistant prostate cancer (mCRPC) is one of the most common cancers with a poor prognosis. To improve prognostic models of mCRPC, the Dialogue for Reverse Engineering Assessments and Methods (DREAM) Consortium organized a crowdsourced competition known as the Prostate Cancer DREAM Challenge. In the competition, data from four phase III clinical trials were utilized. A total of 1600 patients’ clinical information across three of the trials was used to generate prognostic models, whereas one of the datasets (313 patients) was held out for blinded validation. The previously introduced prognostic model of overall survival of chemotherapy-naive mCRPC patients treated with docetaxel or prednisone (so called Halabi model) was used as a performance baseline. This paper presents the model developed by the team TYTDreamChallenge and its improved version to predict the prognosis of mCRPC patients within the first 30 months after starting the treatment based on available clinical features of each patient. In particular, by replacing our original larger set of eleven features with a smaller more carefully selected set of only five features the prediction performance on the independent validation cohort increased up to 5.4 percent. While the original TYTDreamChallenge model (iAUC=0.748) performed similarly as the performance-baseline model developed by Halabi et al. (iAUC=0.743), the improved post-challenge model (iAUC=0.779) showed markedly improved performance by using only PSA, ALP, AST, HB, and LESIONS as features. This highlights the importance of the selection of the clinical features when developing the predictive models.

A Predictive Model of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer